Wed, December 11, 2024
Tue, December 10, 2024
[ Tue, Dec 10th 2024 ] - The New Yorker
The Dawn of the Bionic Man
[ Tue, Dec 10th 2024 ] - Mercury News
California News
[ Tue, Dec 10th 2024 ] - ABC News
Entertainment News
Mon, December 9, 2024
[ Mon, Dec 09th 2024 ] - BBC
Beds, Herts & Bucks
[ Mon, Dec 09th 2024 ] - Uproxx
The Best TV Shows Of 2024
[ Mon, Dec 09th 2024 ] - Paste
The 25 Best PC Games of 2024
[ Mon, Dec 09th 2024 ] - CNET
Top News Stories
Sun, December 8, 2024
Sat, December 7, 2024
[ Sat, Dec 07th 2024 ] - Newsweek
Russia-Ukraine War
[ Sat, Dec 07th 2024 ] - imdb.com
Canada's 30 Funniest TV Shows
[ Sat, Dec 07th 2024 ] - Daily Mail
UK Celebrity News
[ Sat, Dec 07th 2024 ] - Food Safety News
Food Safety News
Fri, December 6, 2024
[ Fri, Dec 06th 2024 ] - Graphic
Latest Ghana News Headlines Today
[ Fri, Dec 06th 2024 ] - The Columbian
Clark County News
[ Fri, Dec 06th 2024 ] - who13
Cyclones react to 10 wins
[ Fri, Dec 06th 2024 ] - TravelPulse
Hotels and Resorts News
[ Fri, Dec 06th 2024 ] - Business Standard
Share Market Today
[ Fri, Dec 06th 2024 ] - Reuters
Aerospace & Defense
Thu, December 5, 2024
[ Thu, Dec 05th 2024 ] - Interest
All news stories
[ Thu, Dec 05th 2024 ] - Stereogum
When Comedians Make Serious Music
[ Thu, Dec 05th 2024 ] - Paste
The 30 Best TV Shows of 2024
[ Thu, Dec 05th 2024 ] - Phil Bruner
Featured News Stories
[ Thu, Dec 05th 2024 ] - Phil Bruner
Swattie Survival Guide
Wed, December 4, 2024
[ Wed, Dec 04th 2024 ] - Phil Bruner
California News
[ Wed, Dec 04th 2024 ] - Phil Bruner
President Joe Biden
Tue, December 3, 2024
[ Tue, Dec 03rd 2024 ] - Phil Bruner
The 40 Best Games of 2024
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Boku No Roblox Codes
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Yonhap News Agency
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Beds, Herts & Bucks
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Transfer news and rumors
Mon, December 2, 2024
[ Mon, Dec 02nd 2024 ] - Phil Bruner
Watch Samaa News Live
[ Mon, Dec 02nd 2024 ] - Phil Bruner
UK Celebrity News
[ Mon, Dec 02nd 2024 ] - Phil Bruner
The 100 Best Albums of 2024
[ Mon, Dec 02nd 2024 ] - Phil Bruner
From the Newspaper
[ Mon, Dec 02nd 2024 ] - Phil Bruner
South Australia
[ Mon, Dec 02nd 2024 ] - Phil Bruner
Whanganui Chronicle
Sun, December 1, 2024
[ Sun, Dec 01st 2024 ] - Phil Bruner
Wildlife Oddities of the Week
Sat, November 30, 2024
Fri, November 29, 2024
[ Fri, Nov 29th 2024 ] - Phil Bruner
Hotels and Resorts News
[ Fri, Nov 29th 2024 ] - Phil Bruner
The Best Jokes of 2024
Thu, November 28, 2024
[ Thu, Nov 28th 2024 ] - Phil Bruner
Climate and Environment
[ Thu, Nov 28th 2024 ] - Phil Bruner
December 2024 Issue
Wed, November 27, 2024
[ Wed, Nov 27th 2024 ] - Phil Bruner
Decoding Gen Z's content diet
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ] - Phil Bruner
Illustrated Humor in the News
[ Tue, Nov 26th 2024 ] - Phil Bruner
World News
[ Tue, Nov 26th 2024 ] - Phil Bruner
Alexandra Petri
Mon, November 25, 2024
[ Mon, Nov 25th 2024 ] - Phil Bruner
Legal IT's Leading News Source
[ Mon, Nov 25th 2024 ] - Phil Bruner
All Kent news
Sun, November 24, 2024
Mon, December 15, 2008
[ Mon, Dec 15th 2008 ] - Market Wire
fasdfasddva s gfg h

OmniComm's TrialMaster(TM) EDC Solution Selected by Leading Medical Device Manufacturer for Phase IV Cardiovascular Device Stud


//science-technology.news-articles.net/content/2 .. rer-for-phase-iv-cardiovascular-device-stud.html
Published in Science and Technology on Tuesday, November 17th 2009 at 6:18 GMT by Market Wire   Print publication without navigation


FORT LAUDERDALE, FL--(Marketwire - November 17, 2009) - OmniComm Systems, Inc. (OTCBB: [ OMCM ]), one of the fastest growing companies in the EDC marketplace, announced today that a leader in the medical device industry has selected OmniComm's TrialMaster EDC solution for the data capture of a Phase IV cardiovascular study. The 24-month, 7-site study will enroll 100 subjects.

"We look forward to continuing our successful collaboration with this device company," remarked Stephen Johnson, COO of OmniComm Systems. "Our flagship EDC solution, TrialMaster, has already proven to be an efficient and reliable data capture system for 12 of this customer's studies during the past 5 years. This is proof positive that the high quality of our EDC solutions and our outstanding customer service continue to generate the high percentage of return business needed to sustain our current rate of growth."

About OmniComm

OmniComm Systems, Inc. ([ www.OmniComm.com ]) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to large-scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


Publication Contributing Sources